Skip to main content
OpenTrials
Completed

NCT Number: NCT06444893

Morphofunctional, Gene, Inflammation Molecules and Oxidative Stress Analysis in Kidney Tissue of COVID-19 Patients

The involvement of the kidneys in patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the outset of the pandemic was associated with high mortality rates worldwide. This was in part due to the generation of an inflammatory process and exacerbated oxidative stress. The present study was initiated to investigate the relationship between morphofunctional changes and gene expression in the kidney tissue of deceased Mexican patients prior to the initiation of vaccination.

The investigator designed a single-center, prospective, cohort study, to analyze and relate the morphofunctional changes and gene expression of inflammatory and oxidative stress molecules in the kidney tissue of men who died from severe COVID-19. A total of 40 percutaneous renal biopsies from deceased patients with severe acute respiratory syndrome coronavirus 2 infection were included in the study and divided into two a groups. One group was preserved in trizol to obtain RNA and total protein, while the remaining sample was fixed in formalin to be examined by staining with hematoxylin and eosin. The histopathological analysis was conducted by an experienced pathologist. The expression of molecules was evaluated by real-time polymerase chain reaction assay (nphs2, slc9a1, cx3cl1, havcr1, slc22a17, sod2, egf, timp2, hmox1, fabp1, and so forth). The following biomarkers were analyzed: interleukin-6, Arginase-1 (Arg-1), Dipeptidyl peptidase-4 (DPP-4), GSTT1, type I gamma-glutamyltransferase (GGT1), Occludin (OCL), CYP3A4, and Claudin-8 (CL-8). Additionally, Western blot analysis was conducted on claudin-5 (CL-5), occludin, HSP70, Nuclear factor erythroid 2-related factor-2 (NRF-2), superoxide dismutase-2 (SOD-2), nicotinamide adenine dinucleotide phosphate dehydrogenase 1 (NQO1), Gamma glutamylcysteine synthase (γ-GCL), and receptor for advanced glycation end products (RAGE). The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, with the subjects divided into two groups based on their eGFR: >60 or <60 ml/min/1.73 m². The statistical analysis was conducted using the Stata program and GraphPad software, version 10.2.3.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Coronaviridae Infections Coronavirus Infections Gene Amplification Infections Inflammatory Response Kidney Injury Lung Diseases Nidovirales Infections Oxidative Stress Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

15 year–80 year

Sex eligibility

Male

Study type

Observational

Primary location

National Institute of Respiratory Diseases

Mexico City, 14080, Mexico

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Not having at least one creatinine measurement.
  • Family members will not accept to participate.

Exclusion criteria

  • Specimens with sub-optimal quality for analysis.

Treatment and study plan

Primary outcomes

  1. Fibrosis and sclerosis scores for identifying morphological changes in kidney tissue.

    Time frame: From the date of postmortem kidney biopsy until the date of histopathological report, in average seven days.

    Morphological changes were evaluated by the fibrosis and sclerosis scores (mild, moderate and severe), using direct visualization of nephron compartments (glomerular and tubulointerstitial) of patients who died due to severe COVID-19.

  2. The estimated glomerular filtration rate for evaluating functional changes. The estimated glomerular filtration rate for evaluating functional changes.

    Time frame: From the date of arrival at the hospital until the date of death, in average one month.

    Functional changes were calculated using the estimated glomerular filtration rate (> 60 vs < 60 ml/min/1.73m2) of patients who died due to severe COVID-19.

Secondary outcomes

  1. Differential gene expression using polymerase chain reaction

    Time frame: From the date of postmortem kidney biopsy until the date of measure of differential gene expression, evaluated in 72 months.

    Changes in differential gene expression in the kidney tissue of patients who died from due to severe COVID-19.

  2. Quantity of inflammatory molecules expressed in picograms of proteins.

    Time frame: From the date of postmortem kidney biopsy until the date of measure the inflammatory molecules expressed in the tissue, evaluated in 72 months.

    Changes in the quantity of inflammatory molecules in the kidney tissue of patients who died due to severe COVID-19.

  3. Quantity of oxidative stress molecules expressed in picograms of proteins.

    Time frame: From the date of postmortem kidney biopsy to the date of measure of oxidative stress molecules expressed in the tissue report, evaluated in 72 months.

    Changes in the quantity of oxidative stress molecules expressed in the kidney tissues of patients who died due to severe COVID-19.

Sponsors and collaborators

Lead sponsor

Instituto Nacional de Enfermedades Respiratorias

Other Gov

Registry information

Official study title

Morphofunctional Analysis, Gene Expression of Inflammation Molecules and Response Mechanisms to Oxidative Stress in Kidney Tissue of Deceased Patients With COVID-19: "Ancestral Variant"

Important dates

Study start
2020
Primary completion
2020
Study completion
2023
First posted
Jun 6, 2024
Registry last updated
Jun 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.